Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 13/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30671498 | 0.87 | CTSL (0.39) | CTSACTSLCTSKITGB3ITGA2B | |
| SCHEMBL30541441 | 0.87 | CTSL (0.39) | CTSACTSLCTSKITGB3ITGA2B | |
| SCHEMBL22837967 | 0.87 | CTSL (0.39) | CTSACTSLCTSKITGB3ITGA2B | |
| SCHEMBL29219865 | 0.87 | CTSL (0.39) | CTSACTSLCTSKITGB3ITGA2B | |
| SCHEMBL20546340 | 0.82 | CASP3 (0.41) | ITGB3ITGA2B | |
| SCHEMBL20546099 | 0.80 | EEF2K (0.42) | CTSA | |
| SCHEMBL21271476 | 0.79 | ITGB3 (0.48) | ITGB3ITGA2B | |
| SCHEMBL28372690 | 0.78 | CTSA (0.47) | CTSACTSLCTSKITGB3ITGA2B | |
| SCHEMBL28238011 | 0.78 | EEF2K (0.40) | CTSAITGB3ITGA2B | |
| SCHEMBL20545829 | 0.77 | CTSA (0.46) | CTSASUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3615514-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2018201167-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885CTSL 2956/4885CTSK 3987/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885CTSL 2956/4885CTSK 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.